Cerebrospinal fluid NrCAM is not a suitable biomarker to discriminate between dementia disorders-a pilot study

Journal of Alzheimer's Disease

Volumn 46, Issue 3, 2015, Pages 605-609

  Müller, Mareike ^a   Claassen, Jurgen A ^a   Kuiperij, H Bea ^a   Verbeek, Marcel M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; biological markers; cerebrospinal fluid; dementia with Lewy bodies; frontotemporal dementia; NrCAM

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; NERVE CELL ADHESION MOLECULE; TAU PROTEIN; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; NRCAM PROTEIN, HUMAN;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC VALUE; DIFFUSE LEWY BODY DISEASE; DISEASE MARKER; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; VALIDITY; CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; MIDDLE AGED; NETHERLANDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOMARKERS; CELL ADHESION MOLECULES; DEMENTIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMANS; LEWY BODY DISEASE; MALE; MIDDLE AGED; NETHERLANDS; PILOT PROJECTS;

EID: 84934291820     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-142901     Document Type: Article

References (17)

1. Rosen C, Hansson O, Blennow K, Zetterberg H (2013) Fluid biomarkers in Alzheimer's disease-current concepts. Mol Neurodegener 8, 20.
2. Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, Pickering E, Kuhn M, Chen Y, McCluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ (2010) Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol 119, 669-678.
3. Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, Roe CM, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, Kaye JA, Morris JC, Holtzman DM, Townsend RR, Fagan AM (2011) Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One 6, e16032.
4. Wildsmith KR, Schauer SP, Smith AM, Arnott D, Zhu Y, Haznedar J, Kaur S, Mathews WR, Honigberg LA (2014) Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted pro-teomics. Mol Neurodegener 9, 22.
5. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report ofthe NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
6. McKeith IG (2006) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop. J Alzheimers Dis 9, 417-423.
7. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF (1998) Frontotempo-ral lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 51, 1546-1554.
8. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Schel-tens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
9. Wang B, Williams H, Du JS, Terrett J, Kenwrick S (1998) Alternative Splicing of Human NrCAM in Neural and Non-neural Tissues. Mol Cell Neurosci 10, 287-295.
10. Conacci-Sorrell M, Kaplan A, Raveh S, Gavert N, Sakurai T, Ben-Ze'ev A (2005) The shed ectodomain of Nr-CAM stimulates cell proliferation and motility, and confers cell transformation. Cancer Res 65, 11605-11612.
11. Sakurai T, Lustig M, Babiarz J, Furley AJ, Tait S, Brophy PJ, Brown SA, Brown LY, Mason CA, Grumet M (2001) Overlapping functions of the cell adhesion molecules Nr-CAM and L1 in cerebellar granule cell development. J Cell Biol 154, 1259-1273.
12. Backer S, Sakurai T, Grumet M, Sotelo C, Bloch-Gallego E (2002) Nr-CAM and TAG-1 are expressed in distinct populations of developing precerebellar and cerebellar neurons. Neuroscience 113, 743-748.
13. Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ (2010) Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol 45, 30-40.
14. Rogelj B, Easton LE, Bogu GK, Stanton LW, Rot G, Curk T, Zupan B, Sugimoto Y, Modic M, Haberman N, Tollervey J, Fujii R, Takumi T, Shaw CE, Ule J (2012) Widespread binding of FUS along nascent RNA regulates alternative splicing in the brain. Sci Rep 2, 603.
15. Lagier-Tourenne C, Polymenidou M, Hutt KR, Vu AQ, Baughn M, Huelga SC, Clutario KM, Ling SC, Liang TY, Mazur C, Wancewicz E, Kim AS, Watt A, Freier S, Hicks GG, Donohue JP, Shiue L, Bennett CF, Ravits J, Cleveland DW, Yeo GW (2012) Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat Neurosci 15, 1488-1497.
16. Ishigaki S, Masuda A, Fujioka Y, Iguchi Y, Katsuno M, Shi-bata A, Urano F, Sobue G, Ohno K (2012) Position-dependent FUS-RNA interactions regulate alternative splicing events and transcriptions. Sci Rep 2, 529.
17. Orozco D, Tahirovic S, Rentzsch K, Schwenk BM, Haass C, Edbauer D (2012) Loss of fused in sarcoma (FUS) promotes pathological Tau splicing. EMBO Rep 13, 759-764.